PMID- 36467087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221206
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance 
      study of the FDA adverse event reporting system (FAERS).
PG  - 1017889
LID - 10.3389/fphar.2022.1017889 [doi]
LID - 1017889
AB  - Background: The purpose of this study is to identify and characterize ocular 
      adverse events (AEs) that are significantly associated with anti-VEGF drugs for 
      treatment of neovascular age-related macular degeneration and compare the 
      differences between each drug, and provide clinical reference. Methods: Ocular 
      AEs submitted to the US Food and Drug Administration were analyzed to map the 
      safety profile of anti-VEGF drugs. The Pharmacovigilance tools used for the 
      quantitative detection of signals were reporting odds ratio and bayesian 
      confidence propagation neural network. Results: A total of 10,608,503 AE reports 
      were retrieved from FAERS, with 20,836 for ranibizumab, 19,107 for aflibercept, 
      and 2,442 for brolucizumab between the reporting period of Q1, 2004 and Q3, 2021. 
      We found and analyzed the different AEs with the strongest signal in each 
      drug-ranibizumab-macular ischaemia (ROR = 205.27, IC-2SD = 3.70), retinal pigment 
      epithelial tear (ROR = 836.54, IC-2SD = 7.19); aflibercept-intraocular pressure 
      increased (ROR = 31.09, IC-2SD = 4.61), endophthalmitis (ROR = 178.27, IC-2SD = 
      6.70); brolucizumab-retinal vasculitis (ROR = 2930.41, IC-2SD = 7.47) and/or 
      retinal artery occlusion (ROR = 391.11, IC-2SD = 6.10), dry eye (ROR = 12.48, 
      IC-2SD = 2.88). Conclusion: The presence of AEs should bring clinical attention. 
      The use of anti-VEGF drugs should be based on the patient's underlying or present 
      medical condition to reduce any adverse event associated with the treatment.
CI  - Copyright (c) 2022 Ma, Pan, Liu, Qu, Xie, Xie, Cao and Chen.
FAU - Ma, Pan
AU  - Ma P
AD  - Department of Pharmacy, The First Affiliated Hospital of Army Medical University, 
      Chongqing, China.
FAU - Pan, Xinmei
AU  - Pan X
AD  - Department of Pharmacy, The First Affiliated Hospital of Army Medical University, 
      Chongqing, China.
FAU - Liu, Ruixiang
AU  - Liu R
AD  - Department of Pharmacy, The First Affiliated Hospital of Army Medical University, 
      Chongqing, China.
FAU - Qu, Ya
AU  - Qu Y
AD  - Southwest Hospital/Southwest Eye Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
FAU - Xie, Linli
AU  - Xie L
AD  - Department of Pharmacy, The First Affiliated Hospital of Army Medical University, 
      Chongqing, China.
FAU - Xie, Jiangchuan
AU  - Xie J
AD  - Department of Pharmacy, The First Affiliated Hospital of Army Medical University, 
      Chongqing, China.
FAU - Cao, Liya
AU  - Cao L
AD  - Department of Pharmacy, The First Affiliated Hospital of Army Medical University, 
      Chongqing, China.
FAU - Chen, Yongchuan
AU  - Chen Y
AD  - Department of Pharmacy, The First Affiliated Hospital of Army Medical University, 
      Chongqing, China.
LA  - eng
PT  - Journal Article
DEP - 20221118
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9716077
OTO - NOTNLM
OT  - adverse events
OT  - aflibercept
OT  - brolucizumab
OT  - pharmacovigilance
OT  - ranibizumab
OT  - safety signals
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/06 06:00
MHDA- 2022/12/06 06:01
PMCR- 2022/11/18
CRDT- 2022/12/05 04:17
PHST- 2022/08/12 00:00 [received]
PHST- 2022/11/07 00:00 [accepted]
PHST- 2022/12/05 04:17 [entrez]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/06 06:01 [medline]
PHST- 2022/11/18 00:00 [pmc-release]
AID - 1017889 [pii]
AID - 10.3389/fphar.2022.1017889 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Nov 18;13:1017889. doi: 10.3389/fphar.2022.1017889. 
      eCollection 2022.